Also known as Kahler's disease, myelomatosis or plasma cell myeloma, this type of blood cancer attacks the white blood cells responsible for the production of antibodies, and it also happens to be the third most common blood cancer in the world - which is why the world was in serious need of a new multiple myeloma treatment.
Over time, Science Daily has reported on a number of breakthroughs regarding multiple melanoma treatment, including the most recent advance of multiple-drug treatment for the disease, combining three different ones: investigational drug ixazomib taken orally, along with lenalidomine and dexamethasone, which have shown promise in various stages of scientific development.
According to Reuters, the latest multiple melanoma treatment news sees that Bristol-Myers Squibb biotech's trials with experimental drug elotumazub, the name of the combined treatment, have seen an important increase of life expectancy and remission time for those who have taken it.
Pharma Times reports that the new multiple melanoma treatment was recently used on a 646-patient trial called ELOQUENT-2, as they added the new component to existing treatment; it turns out that the Phase III data from the tests showed progression risk of the cancer cut back by 30 percent, as well as extending remission from 14.9 (without the new drug) to 19.4 months (with the combined treatment).
Asia One reports that the new multiple melanoma treatment is a type of immune therapy, as elotumazub is a monoclonal antibody (which is to say, a type of immune cell).
The treatment was created in conjunction between Bristol Myers-Squibb and pharmaceutical research company AbbVie, and the latest results were recently launched right before this year's American Society of Clinical Oncology conference, which is set to be held this very month in Chicago.
In 2014, the new multiple melanoma treatment received the "breakthrough" designation from the Food and Drug Administration (FDA), a designation that's given to medicines that could turn into potentially major advances in health.
